To accelerate the development of smart medical examination, Kingdomain Medical signed a strategic cooperation agreement with Tencent
In order to promote the construction of smart medical examination industry and help the medical industry achieve high-quality development, Kingdomain Medical officially signed a strategic cooperation agreement with Tencent on February 23. The two sides will carry out in-depth cooperation in the digital upgrading of medical laboratory and pathological diagnosis, intelligent medical examination services, and clinical application exploration of medical examination AI, so as to radiate better technical resources into the medical examination industry chain, jointly create intelligent medical examination, and help the medical industry achieve high-quality development.
Liang Yaoming, Chairman and CEO of Kingfield Medical Group; Li Huiyuan and Li Yinghua, vice presidents; Liang Xiaodan, general manager of Digital Operation Management Center; Tang Daosheng, senior Executive Vice President of Tencent Group and CEO of Cloud and Wisdom Industry business Group; Wu Wenda, Vice president of Tencent Health; Fan Yong, chief solution architect of Tencent Health and Wisdom Medical; Witnessed by Zheng Yefeng, Director of Tencent Tianyan Laboratory, Xie Jiangtao, Vice president of Kingfield Medical Group, and Zhang Guodong, general manager of Tencent Health and Smart Medicine, signed a strategic cooperation agreement on behalf of both sides.
Liang Yaoming said, "Since the launch of digital transformation, Kingland Medical has achieved initial results in the construction of smart medical examination ecology. This collaboration will accelerate and upgrade digital transformation efforts. We look forward to a strong synergy between the two sides in the future to contribute to the high-quality development of digital healthcare systems and make quality healthcare resources more universally accessible."
"The entire medical and health industry is accelerating digitalization, and Tencent is focusing on its core strengths to help the high-quality development of the medical and health industry with digital technology," Tang said.
Golden Domain Medicine is the pioneer and leader of the third party medical inspection industry in China. As early as 2020, Kingdomain Medical seized the digital opportunity, relying on the comprehensive and high-quality medical examination technology platform and the service network covering the whole country, fully layout the smart medical examination industry ecology, drawing a new blueprint of "medical examination 4.0" in China. At present, Kingdomain Medical has made a series of progress in the field of smart medical examination, one-stop customer service platform, department information + intelligent system focusing on AI pathology and clinical assisted diagnosis, smart laboratory and other new projects of smart medical examination exploration and construction have achieved initial results.
Tencent Cloud integrates cloud computing, AI, big data, cloud security and other technical capabilities, products and solutions, is comprehensively promoting industrial digital upgrading. In the medical and health field, Tencent Health continues to promote the deep combination of science and technology and medicine, exploring new industrial integration models such as Sopohui medical and precision medicine. In the process of building a new generation of artificial intelligence open platform for medical imaging country, its Tencent Miying has obtained "three class certificates" of medical AI in different specialty fields, formed mature solutions in medical imaging, digital pathology and other fields, vigorously promoted the construction of open experimental platform, and helped medical AI innovation cooperation and achievement transformation.
In this cooperation, the two sides will form joint forces in the exploration and application of medical laboratory AI, intelligent medical examination services and other digital transformation fields, so as to promote the construction of intelligent medical examination ecology. In terms of medical laboratory AI, the two sides will conduct in-depth cooperation in knowledge mapping, multi-omics and multi-modal assisted diagnosis, etc., to promote the efficiency of the medical laboratory industry and help achieve precision diagnosis and treatment. In terms of the improvement of the intelligent level of medical examination service, jointly create the "on line" industry benchmark of medical examination; In terms of digital infrastructure construction such as enterprise data service, digital base and security protection system, as well as ecological co-construction such as personnel exchange, technical cooperation and channel integration, complementary advantages and deep integration are realized.
Looking for chemical products? Let suppliers reach out to you!
2026-07-04
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Unable to get the new crown vaccine for medical reasons What can I do to protect myself?
-
Promoting the Level of Primary Medical Care
-
Alipay, Baidu, and iFlytek Win Big—As the Government Spends $1.1 Billion on AI Healthcare, Is This a Lifeline or a Feeding Frenzy for Tech Giants?
-
Indian Immunologicals Pushes Back on “Fake Vaccine” Claims Amid Global Supply Chain Scrutiny
-
Obesity Drugs Become Pharma’s Most Powerful Growth Engine
-
Substandard Drug Findings Expose Deep Structural Gaps in Medicine Quality Control
-
Minoxidil Safety Under Global Review as Infant Exposure Risks Surface
-
India Accuses Balaji Amines of Manufacturing Pharma-Grade Propylene Glycol Without Drug Manufacturing Licence
-
Roche Takes Natco to Supreme Court Over Generic Risdiplam Launch in India
-
Sun Pharma’s Ilumya Hits Primary Endpoint in Two Phase 3 Trials for Psoriatic Arthritis $681 Million Drug Shows Significant Improvement at Week 24
Recommend Reading
-
Bristol Myers’ Reblozyl Misses Main Goal in Cancer Anemia Study $1.77 Billion Drug Faces Setback but Shows Some Benefits
-
Bayer’s Ambitious Gene & Cell Therapy Pipeline Eyes Parkinson’s, Oncology, Rare Diseases
-
Sanofi’s $2.2 Billion Dynavax Acquisition: Why Big Pharma Is Rebuilding the Global Vaccine Order
-
J&J to Spin Off Orthopedics Business, Raises 2025 Forecast
-
Bristol Myers Squibb Launches Mavacamten (“Kopozgo”) in India for Obstructive Hypertrophic Cardiomyopathy
-
Brazil Launches EficazControl Biocontrol Agent Yields Up 3.71 Bags per Hectare Approved for Soybean Corn Disease Protection
-
China's Natural Rubber Market Narrowly Consolidates
-
On October 29, the domestic anhydrous hydrogen fluoride market in China saw a slight downward adjustment
-
EPA Reviews Bayer’s New Fungicide Fluoxapiprolin for US Crops Disease Control Expanded Risk Assessed as Low
-
Cost support strong, anhydrous hydrogen fluoride market remains firm and tends to strengthen (12.22-12.26)